5-((5-Chloro-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one

ID: ALA4458261

Chembl Id: CHEMBL4458261

PubChem CID: 142478626

Max Phase: Preclinical

Molecular Formula: C24H34ClN7O2

Molecular Weight: 488.04

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1CN(c2ncc(Cl)c(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C[C@H](C)N1C

Standard InChI:  InChI=1S/C24H34ClN7O2/c1-15-13-31(14-16(2)29(15)5)22-26-12-18(25)21(28-22)27-17-7-8-19-20(11-17)32(23(33)30(19)6)10-9-24(3,4)34/h7-8,11-12,15-16,34H,9-10,13-14H2,1-6H3,(H,26,27,28)/t15-,16+

Standard InChI Key:  PBAFOBIJSSTSFA-IYBDPMFKSA-N

Alternative Forms

  1. Parent:

    ALA4458261

    ---

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCOR2 Tchem BCL-6/NCOR2 (21 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 488.04Molecular Weight (Monoisotopic): 487.2463AlogP: 3.22#Rotatable Bonds: 6
Polar Surface Area: 91.45Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.72CX LogP: 3.48CX LogD: 2.99
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.55Np Likeness Score: -1.01

References

1. Bellenie BR, Cheung KJ, Varela A, Pierrat OA, Collie GW, Box GM, Bright MD, Gowan S, Hayes A, Rodrigues MJ, Shetty KN, Carter M, Davis OA, Henley AT, Innocenti P, Johnson LD, Liu M, de Klerk S, Le Bihan YV, Lloyd MG, McAndrew PC, Shehu E, Talbot R, Woodward HL, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Hoelder S..  (2020)  Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.,  63  (8): [PMID:32275432] [10.1021/acs.jmedchem.9b02076]

Source